MX2023010316A - Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. - Google Patents
Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.Info
- Publication number
- MX2023010316A MX2023010316A MX2023010316A MX2023010316A MX2023010316A MX 2023010316 A MX2023010316 A MX 2023010316A MX 2023010316 A MX2023010316 A MX 2023010316A MX 2023010316 A MX2023010316 A MX 2023010316A MX 2023010316 A MX2023010316 A MX 2023010316A
- Authority
- MX
- Mexico
- Prior art keywords
- indole derivatives
- treatment
- agents useful
- disorders related
- disorders
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 208000035475 disorder Diseases 0.000 title abstract 3
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 title 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical class C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente solicitud se refiere a derivados de 3-amino-indol de la Fórmula general (I-B), a procesos para su preparación, a composiciones que los comprenden y a su uso en la activación de receptores de serotonina en una célula, así como al tratamiento de enfermedades, trastornos o condiciones por activación de receptores de serotonina en una célula. Las enfermedades, trastornos o afecciones incluyen, por ejemplo, psicosis, enfermedades mentales y trastornos del SNC. (ver formula) Fórmula (I-B).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163155634P | 2021-03-02 | 2021-03-02 | |
| PCT/CA2022/050296 WO2022183288A1 (en) | 2021-03-02 | 2022-03-02 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010316A true MX2023010316A (es) | 2023-11-09 |
Family
ID=83153685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010317A MX2023010317A (es) | 2021-03-02 | 2022-03-02 | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
| MX2023010316A MX2023010316A (es) | 2021-03-02 | 2022-03-02 | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010317A MX2023010317A (es) | 2021-03-02 | 2022-03-02 | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240166630A1 (es) |
| EP (2) | EP4301747A1 (es) |
| JP (2) | JP2024508545A (es) |
| KR (2) | KR20230154219A (es) |
| CN (2) | CN117500788A (es) |
| AU (2) | AU2022229037A1 (es) |
| BR (1) | BR112023017754A2 (es) |
| CA (2) | CA3210270A1 (es) |
| IL (2) | IL305481A (es) |
| MX (2) | MX2023010317A (es) |
| WO (2) | WO2022183288A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230219889A1 (en) | 2020-05-19 | 2023-07-13 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| WO2024046837A1 (en) * | 2022-08-31 | 2024-03-07 | Cybin Irl Limited | Tryptamine compounds, compositions, and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL220721B1 (pl) * | 2001-03-29 | 2015-12-31 | Lilly Co Eli | Związki będące pochodnymi N-(indolilo-2-etylo) benzyloaminy, kompozycja farmaceutyczna oraz zastosowanie |
| TWI318621B (en) * | 2006-08-03 | 2009-12-21 | Nat Bureau Of Controlled Drugs Dept Of Health | A series of deuterium labelled compounds as drug testing standards and their preparations |
| US20090062367A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched eletriptan |
| BR112014005286B1 (pt) * | 2011-09-09 | 2022-08-23 | Lantheus Medical Imaging, Inc | Compostos de um primeiro e um segundo agente de imageamento para determinar incompatibilidade de inervação e perfusão na parte do indivíduo |
| US20190358238A1 (en) * | 2016-11-16 | 2019-11-28 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| BR112021017621A2 (pt) * | 2019-03-07 | 2021-11-23 | Arbormentis LLC | Composições e métodos de uso compreendendo substâncias com ações de plasticidade neural administradas em dosagens e formulações não psicodélicas/psicotomiméticas |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| EP4100403A4 (en) * | 2020-02-04 | 2024-01-03 | Mindset Pharma Inc. | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONINERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS |
| JP2023513680A (ja) * | 2020-02-04 | 2023-04-03 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| TW202144369A (zh) * | 2020-04-26 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 海鞘素類衍生物及其製備方法與醫藥用途 |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
-
2022
- 2022-03-02 AU AU2022229037A patent/AU2022229037A1/en active Pending
- 2022-03-02 BR BR112023017754A patent/BR112023017754A2/pt unknown
- 2022-03-02 CA CA3210270A patent/CA3210270A1/en active Pending
- 2022-03-02 CN CN202280032370.6A patent/CN117500788A/zh active Pending
- 2022-03-02 JP JP2023553660A patent/JP2024508545A/ja active Pending
- 2022-03-02 CA CA3210275A patent/CA3210275A1/en active Pending
- 2022-03-02 US US18/279,293 patent/US20240166630A1/en active Pending
- 2022-03-02 KR KR1020237033351A patent/KR20230154219A/ko unknown
- 2022-03-02 WO PCT/CA2022/050296 patent/WO2022183288A1/en active Application Filing
- 2022-03-02 MX MX2023010317A patent/MX2023010317A/es unknown
- 2022-03-02 AU AU2022229695A patent/AU2022229695A1/en active Pending
- 2022-03-02 MX MX2023010316A patent/MX2023010316A/es unknown
- 2022-03-02 JP JP2023553664A patent/JP2024508922A/ja active Pending
- 2022-03-02 US US18/279,290 patent/US20240166599A1/en active Pending
- 2022-03-02 IL IL305481A patent/IL305481A/en unknown
- 2022-03-02 KR KR1020237033368A patent/KR20230154220A/ko unknown
- 2022-03-02 WO PCT/CA2022/050295 patent/WO2022183287A1/en active Application Filing
- 2022-03-02 IL IL305622A patent/IL305622A/en unknown
- 2022-03-02 EP EP22762290.9A patent/EP4301747A1/en active Pending
- 2022-03-02 CN CN202280032373.XA patent/CN117242065A/zh active Pending
- 2022-03-02 EP EP22762289.1A patent/EP4301730A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117500788A (zh) | 2024-02-02 |
| MX2023010317A (es) | 2023-11-09 |
| AU2022229037A1 (en) | 2023-09-28 |
| KR20230154219A (ko) | 2023-11-07 |
| IL305481A (en) | 2023-10-01 |
| EP4301730A1 (en) | 2024-01-10 |
| EP4301747A1 (en) | 2024-01-10 |
| IL305622A (en) | 2023-11-01 |
| JP2024508545A (ja) | 2024-02-27 |
| US20240166630A1 (en) | 2024-05-23 |
| AU2022229695A1 (en) | 2023-09-28 |
| US20240166599A1 (en) | 2024-05-23 |
| WO2022183287A1 (en) | 2022-09-09 |
| KR20230154220A (ko) | 2023-11-07 |
| WO2022183288A1 (en) | 2022-09-09 |
| BR112023017754A2 (pt) | 2023-11-21 |
| CA3210275A1 (en) | 2022-09-09 |
| JP2024508922A (ja) | 2024-02-28 |
| CN117242065A (zh) | 2023-12-15 |
| CA3210270A1 (en) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009526A (es) | Derivados de psilocina como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. | |
| MX2022009528A (es) | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. | |
| MX2023010316A (es) | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. | |
| MX2007013021A (es) | Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c. | |
| EA200900658A1 (ru) | Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами | |
| MX2010004819A (es) | Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta. | |
| MX2009005252A (es) | Aminopirrolidinas como antagonistas del receptor de quimiocina. | |
| PH12012501640A1 (en) | Novel compounds as opioid receptor modulators | |
| TNSN07007A1 (en) | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha -7- nachr ligands for the treatment of cns diseases | |
| PH12015500457A1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| MD4489B1 (ro) | Derivaţi de 1,4-benzotiazepină, procedeu de sinteză a lor, compoziţii farmaceutice care le conţin şi utilizarea acestora pentru tratarea sau prevenirea afecţiunilor care implică modularea receptorilor de rianodină | |
| MY147588A (en) | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives | |
| MX2023006652A (es) | Derivados de amina-indol-3-ciclica como agentes serotonergicos para el tratamiento de trastornos del snc. | |
| GB0513886D0 (en) | Novel compounds | |
| MY183111A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| CR20220160A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| MX2021003945A (es) | Compuestos de indolinona para uso como inhibidores de map4k1. | |
| PL1745010T3 (pl) | Podstawione pochodne cykloheksylo-1,4-diaminy | |
| JO2749B1 (en) | Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application | |
| MX2023006063A (es) | Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central. | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| WO2022115944A8 (en) | Carboxylated psilocybin derivatives and methods of using | |
| MX2015008733A (es) | Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma. | |
| UA88910C2 (ru) | Гетероциклические соединения для предотвращения или ослабления симптомов заболеваний, которые лечатся коноплей, и способы их получения | |
| MX2019004782A (es) | Compuestos, proceso de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de trastornos psiquiatricos y/o trastornos del sueño. |